1. Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
- Author
-
Zehao Zheng, Renguo Guan, Rongce Zhao, Junyu Gan, Xinhao Xiong, Jing-wen Zou, Shaohua Li, Qiaoxuan Wang, Wei Wei, Jie Mei, and Rongping Guo
- Subjects
hepatocellular carcinoma ,locoregional therapy ,immunotherapy ,alpha-fetoprotein ,alkaline phosphatase ,eosinophil ,Immunologic diseases. Allergy ,RC581-607 - Abstract
PurposeThe α-FAtE score, composed of alpha-fetoprotein, alkaline phosphatase, and eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab. This study aimed to investigate the predictive ability of α-FAtE score for the efficacy and safety of locoregional immunotherapy as the treatment of HCC patients.Methods and patientsWe conducted a retrospective study of 446 HCC patients at Sun Yat-sen University Cancer Center from January 1st 2019 to January 1st 2023. The predictive performance was evaluated by the concordance index, the area under the receiver operating characteristics curve, the Kaplan-Meier curve and multiple Cox regression analysis.Results446 patients were divided into the α-FAtE 0-1 group (n=211) and α-FAtE 2-3 group (n=235). The median progression-free survival(PFS) of the α-FAtE 0-1 group and 2-3 group was 7.3 months (95%CI 6.6-8.7 months), and 12.3 months (95% CI 10.4–14.1 months; P
- Published
- 2025
- Full Text
- View/download PDF